Co-founded and funded with Julian Robertson, Tiger Management.TigerGene LLC is a venture capital fund that forms and invests in the most promising early stage life science technologies, ranging from protein engineering platforms for therapeutic development, genomics tools, to AI and healthcare. TigerGene forms the companies around these technologies and works closely with the technical founders and management team to realize the commercial promise of the science.

BrickBio: a TigerGene formed and funded company focused on site specific conjugation at any site, with site specific multiple conjugations. BrickBio is exclusively working with therapeutic partners (pharma and bio-pharma). Exciting partnership just announced with Abcam to expand capabilities across both companies.

NanoMosaic is leveraging the power of nanoneedles for label free, single molecule detection of proteins across seven orders of dynamic range at a cost two orders of magnitude less than current protein interrogation solutions. With a simplified workflow and direct protein interrogation approach, NanoMosaic is poised to change the paradigm in diagnostics and therapeutic development. Www.nanomosaicllc.com

John teaches a class on innovation and entrepreneurship at Harvard. Students learn how to evaluate opportunities and raise capital by: examining company business models and thinking creatively, the actual step by step analysis of technology evaluation - what can be commercial and what should stay in academia , hands on technical and commercial evaluation of actual pre-funding stage technologies (while working with the inventors), how to value an opportunity for a capital raise, and how to create a successful pitch. The class also covers IP strategy, successful company structure in the startup phase, and very importantly - realistic exit strategy to maximize a return for investors, as well as how to choose the right investors for the technology.

John was recently President and CEO of Exosome Diagnostics, a liquid biopsy company which he turned around and drove to a successful acquisition for $575 MM ($250 MM upfront) to Bio-Techne within ~2.5 years, resulting in a ~6X return to investors. John came to the company in October 2015 when the company was critically low on cash and struggling to close its Series B round, with no external investors or acquirers interested. Within ~3 months, John re-positioned the company by implementing a "3 Pillar Strategy", developed a Companion Diagnostics division and Regulatory division, and brought in Tiger Management as an investor, to close the B round for $60MM. Subsequently, John closed an oversubscribed Series C round for $33MM, and drove the company to its successful exit.John set the strategy, restructured the company, built the divisions, hired the division heads, and oversaw the launch of EPI (the company's urine based prostate cancer test). John spearheaded the effort and oversaw the team that allowed the company to achieve a CPT code from AMA within the first 6 months of launch, obtain coverage from Blue Cross Blue Shield (Care First) within the first year of launch (Care First funded the clinical trials - the first time a private payor funded a Coverage with Evidence Based clinical trial). These milestones have occurred within the first year of commercialization - a process that normally takes between 3- 5 years.Within two years after John created the Companion Diagnostics division of the company, it became the worldwide leader in liquid biopsy deals with pharmaceutical companies - signing up to ~$64MM worth of deals. The strategy that John created allowed Exosome Dx to retain any diagnostic intellectual property generated in the work.

John incorporated GnuBIO in December 2009, closed the Series A Round in November 2010, and began operations in January 2011. GnuBIO was acquired by Bio-Rad in April 2014, providing investors with a deal valued at ~6X ROI ($110 MM). GnuBIO/Bio-Rad is producing desktop DNA sequencing systems that provide "Sample In, Answer Out" ease of use to clinicians, thus simplifying powerful diagnostic technology and bringing the power of DNA sequencing to the clinic, drastically improving turn around time for patient samples, and changing the way healthcare is practiced. John set the vision of the company, as well as developed the clinical diagnostics strategy. He incorporated the company in December 2009, identified and licensed the initial intellectual property portfolio from Harvard, built the Advisory Committee and recruited the senior management team.John raised an initial Series A round of $8 MM in November 2010, from which the company was able to produce and ship an Alpha system to a clinical facility in order to run samples by July 2011. John closed an additional round of $10 MM in September 2012, grew the company to 54 employees, and sold the company to Bio-Rad in April 2014, providing investors a significant return.

Delphi Bio was founded to serve the unmet need of providing strategic business planning and commercial positioning, by professionals who have worked for cutting edge biotechnology companies and who have developed detailed commercialization plans in competitive environments. Delphi Bio specializes in working with early stage start up companies in order to help these entities raise funding, develop and execute on a viable business plan, generate revenue, and exit at a favorable return. Working from a unique business model whereby Delphi takes an active role in senior management, the company has developed a creative model of blending equity and cash compensation. The company has generated over $145 MM in returns for investors and shareholders.

John founded, provided funding, and oversaw a staff to run the Consumer Genetics Conference which was the first, large scale, international, conference to thoroughly explore the emerging field of “Direct to Consumer” genetic testing. Through 2011 the conference grew to over 1,000 attendees and featured presentations from thought leaders such as Francis Collins,Director of the NIH, George Church, Professor of Genetics at Harvard Medical School and founder of Harvard’s Personal Genome Project, and many other key opinion leaders in the fields of genetics, politics, ethics, and law.The conference served as the venue where many companies announced groundbreaking product announcements bridging genetics and consumer use, such as Illumina's Genome Browser for the iPhone and iPad.The conference was referenced in numerous scientific publications, as well as mainstream journals. It was also featured on local Boston news programs, and covered by "60 Minutes".In 2012 John sold the conference to Cambridge Healthtech Institute.Watch "Consumer Genetics Conference Interview with John Boyce, President/CEO of GnuBIO" on YouTubehttps://youtu.be/WqfQjXv6q4s

John was able to leverage the Series A raise of $6 MM in July 2008, and sell the company to Illumina in July 2010, providing investors with a ~5X ROI ($28 MM).John wrote the business strategy, planned the media and press release strategies, as well as set up the key scientific collaborations that enabled a successful exit for investors.John identified and obtained access to critical intellectual property, and built the company as the premier source of high throughput scFv production. Affomix was the only source of quantitative proteomic reagents for readout on next generation sequencing systems.

As Head of Business Development for Helicos BioSciences, John was responsible for identifying new market opportunities in which the company was able to develop new applications that gave it a substantial competitive advantage. As a result of this effort, John was able to identify both a market, as well as form a collaborative effort to develop an application, that allowed the company to go public in May 2007. Despite the competitive landscape in the next generation DNA sequencing market and unfavorable market IPO conditions, the company was able to raise $48.6MM and obtain top level banking institutes such as J.P. Morgan, UBS, Pacific Growth equities, and Leerink Swann.

Prior to Helicos, John was the Senior Director of Commercial Development for Parallele Biosciences, Inc. He played an integral role of building the company and orchestrating the sale of the company to Affymetrix for over $120MM within two years after the companies had formed a co-marketing agreement.

John served a distinguished and successful tenure as Director, United States Sales at Sequenom Inc., from FY 2000 to End FY 2003 where he initiated and led the successful expansion of Sequenom's MassARRAY system and consumable business in the United States. John was also responsible for designing and leading a business development and marketing initiative, which paved the path for entry into various key market segments and in total generated the majority of the company's revenue during his tenure (over $93 MM).

John was Head of Product Development and responsible for the development of the company's hollow fiber monoclonal antibody production system. He led a team of engineers and scientists to develop the product to market specifications, as well initiated and ran the company's beta program worldwide. He fostered and developed relationships in major pharmaceutical companies both in the United States and abroad.